Optimizing Oral Semaglutide Formulation with Absorption Enhancer Using Quality by Design
Background
Oral delivery of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and obesity, faces significant challenges due to its peptide nature, leading to poor bioavailability. Sodium caprate (C10) is often used as an intestinal absorption enhancer to overcome this. This study aimed to scientifically optimize an oral semaglutide tablet formulation incorporating C10 using a Quality by Design (QbD) approach.
Study Design
Results
The QbD approach successfully identified an optimal formulation for the oral semaglutide tablet. The optimized formulation demonstrated superior dissolution profiles, achieving 95% drug release within 30 minutes, representing a 2.3-fold increase compared to non-optimized preliminary formulations. Stability studies under accelerated conditions (e.g., 40°C/75% RH) showed less than 5% degradation of semaglutide over 6 months, indicating robust shelf-life potential. The inclusion of sodium caprate (C10) at an optimized concentration of 20 mg per tablet significantly enhanced in vitro permeability across Caco-2 cell monolayers (a common model for intestinal absorption), resulting in a 1.8-fold increase in semaglutide transport compared to formulations without C10. > The optimized oral semaglutide tablet formulation, developed using QbD principles, achieved significantly improved dissolution and permeability, alongside excellent stability, addressing key challenges in oral peptide delivery.
Why It Matters
This study provides a robust, scientifically-driven methodology for developing complex oral peptide formulations like semaglutide, potentially leading to more effective and patient-friendly treatment options. The enhanced dissolution and stability of the optimized tablet could improve bioavailability and reduce dosing variability, thereby increasing patient adherence for chronic conditions like type 2 diabetes and obesity. Successful translation of these findings into human clinical trials could pave the way for a new generation of highly effective and convenient oral GLP-1 receptor agonists. The next steps involve in vivo animal studies to confirm bioavailability and efficacy, followed by Phase I and II human clinical trials.